asa guidelines for glp-1 drugs Holding Agonists Prior to Elective Procedures Perioperative management of patients on

Use of DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors is on the rise owing, at least in part, to their glycemic benefits, lack of weight gain, and complementary mechanisms of action when used in combination with metformin or other antihyperglycemic medication classes

adjusted HR = 3.89, 95% CI: 2.455.12)

Amylin licensed Engs lizard peptide in 1996, and developed a synthetic version, exenatide

The United States is the world's dominant GLP-1 receptor agonist market by an enormous margin, with over 45% of global GLP-1 revenues generated domestically despite representing less than 5% of the world's diabetes and obesity patient population

This work was supported by the National Natural Science Foundation of China (Grant No